Latest Headlines

Does Anemia Protect Children From Malaria?

It is well known that sickle cell trait can protect carriers from developing malaria; yet iron deficiency anemia offers a greater protective effect against malaria than sickle cell trait, according to research published in...

Online Exclusive

U.S. Hospitals Warn About Looming Chemotherapy Shortages

Several U.S. hospitals have reported short supplies of two chemotherapy drugs, vincristine and etoposide. The former is used to treat leukemia and the latter...

Trump Administration Reveals Plans to Lower Drug Prices

In a recent speech at the White House, President Donald Trump unveiled new initiatives to curb high drug prices, including removing barriers to generic-drug...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Pulling Back the Curtain: Brian J. Bolwell, MD

Hear more from our interview with Dr. Bolwell, where he shares what he looks for in new recruits and who his dream dinner party guest...

Pulling Back the Curtain: Olatoyosi Odenike, MD

Hear more from our interview with Dr. Odenike, where she describes finding her home in hematology, and offers advice for early-career doctors.

Big Questions, Tough Answers: Norman “Ned” Sharpless, MD

In more from our interview, Dr. Sharpless shares his vision as National Cancer Institute Director and for overcoming the obstacles to advancing research.

Pulling Back the Curtain: Andra James, MD, MPH

Hear more from our interview with Dr. James, where she shares more about the patients who inspired her to pursue hematology and the importance...

On Location

A Curative Strategy for High-Risk Smoldering Multiple Myeloma?

In a phase II trial of patients with previously untreated smoldering multiple myeloma (SMM), the...

Final Analysis of IFM2009 Trial Confirms Predictive Value of Minimal Residual Disease in Myeloma

Because survival for patients with multiple myeloma (MM) has significantly improved within the past decade,...

Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma

According to final results from the phase III ASPIRE study assessing patients with relapsed/refractory multiple...

Doubling Down on Double Transplant for Myeloma: Updated Results from EMN02/H095

More than a year ago, at the 2016 ASH Annual Meeting, Michele Cavo, MD, from...

BCMA Antibody Drug Conjugate Active in Patients With Heavily Pretreated Myeloma

In a phase I study presented at the 2017 ASH Annual Meeting, 60 percent of...

Early-Phase Study Finds Venetoclax Plus Obinutuzumab Safe and Effective in Patients with Untreated CLL

Venetoclax – a highly selective, potent BCL2 inhibitor – demonstrated significant anti-tumor activity in patients...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
5,635SubscribersSubscribe

Gene Therapy Alleviates Transfusion Burden in Patients With Beta-Thalassemia

Treatment with gene therapy reduced or eliminated the need for long-term red blood–cell (RBC) transfusions in some patients with severe, transfusion-dependent beta-thalassemia, according to...

Can Pevonedistat Improve Azacitidine’s Activity in Older Patients With AML?

Adding pevonedistat, a first-in-class inhibitor of the NEDD8-activating enzyme (NAE), to azacitidine led to responses in patients with acute myeloid leukemia (AML), according to...
WIB_icon

Long-Term PACE Follow-Up Confirms Ponatinib’s Benefit in CP-CML

At five-year follow-up, treatment with the third-generation tyrosine kinase inhibitor (TKI) ponatinib led to deep and durable responses in patients with heavily pretreated chronic-phase...

FDA Approves Nilotinib for Frontline and Secondline Use in Pediatric CML

The FDA approved nilotinib for first- and secondline use in pediatric patients (≥1 year) with Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CP-CML). Approval was...

The Year in FDA Approvals

In the past year, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of myeloid malignancies, including drugs approved for...